Congratulations Circadian

Yesterday’s announcement that Opthea (née Circadian, ASX : CIR) completely restructured its board, is good news for the company – but it is also good news for the biotech industry. Opthea’s board reshuffle, in my opinion, follows on what has been a spate of shareholder backlash to underperforming bioscience companies, and it is great to…

MSB Revalued

A guy goes to a mathematician and asks him how much ONE BILLION plus ONE HUNDRED MILLION equals. The mathematician explains that there are so many different mathematical systems, that he can’t possibly answer that question without lecturing for at least an hour about the philosophical underpinnings of mathematics. The guy next goes to an…

Because an Emu Wouldn’t Fit in the Oven…

One of my great hopes for the Australian biosciences scene is that we get to a stage of market information quality that retail investors can read and use a critical assessment of a biotech stock, and actually take note rather than just get their knickers in a twist. It requires many ecosystem changes but if we want to…

A Little Rest

Hi there… it’s been a while. I hope you are doing fine? You’re looking great, by the way… I took a break. Between a pile of business travel over the past few weeks*, several new ventures getting off the ground and the pending arrival of my second child, I have just been swamped. But I…

Geoff Buys a Gomer

I’ve been waiting for this moment all day, a quiet hour to sit down in my man-cave and tell you all a little story. When I first read about ADO’s acquisition of DIAsource ImmunoAssays, SA (DIAsource) yesterday, a little flicker of neural recognition took place inside my head. Not in the vague way that, for…

BLT : How Not to Raise Money

Firstly, I want to start this post by sincerely congratulating Peter French and the Benitec (ASX : BLT) team for pricing their IPO. I don’t really like most of what this company does but you have to hand it to them for their tenacity and I genuinely admire the staying power. I think a lot of…

No Delirium in Adherium

Well, by now, the cat is out of the bag… and we know that Adherium successfully raised $35m in an oversubscribed share offer, and will list on the ASX (subject to regulator approval) on the 26th of August. It’s sort of nice to see our brethren from across the Tasman come up with something innovative…